Silverarc Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Silverarc Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,315,601	Closed	-$17.3M	–	78
2024 Q4	$17.3M	Buy	+1,315,601	New	+$18M	3.79%	8
2024 Q2	–	Sell	-183,392	Closed	-$2.73M	–	83
2024 Q1	$2.73M	Sell	183,392 -135,132	-42%	-$2.23M	0.76%	41
2023 Q4	$5.77M	Buy	318,524 +68,115	+27%	+$1.04M	1.72%	20
2023 Q3	$4.34M	Buy	250,409 +143,142	+133%	+$2.48M	1.32%	33
2023 Q2	$1.94M	Buy	107,267 +7,267	+7%	+$172K	0.6%	46
2023 Q1	$2.66M	Sell	100,000 -117,503	-54%	-$3.35M	1.1%	35
2022 Q4	$4.2M	Buy	217,503 +7,681	+4%	+$161K	1.2%	34
2022 Q3	$4.38M	Buy	+209,822	New	+$4.01M	1.48%	26

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

Silverarc Capital Management's PLRX Position: Q1 2025 in Review

Silverarc Capital Management sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 1,315,601 shares — an estimated $17.3M sold.

Silverarc Capital Management first reported a position in PLRX in Q3 2022 and held it in 8 quarters. The position peaked at $17.3M in Q4 2024. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

Silverarc Capital Management reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
Silverarc Capital Management sold 1,315,601 Pliant Therapeutics shares in Q1 2025, an estimated $17.3M.
Silverarc Capital Management first reported a position in Pliant Therapeutics in Q3 2022 and held it in 8 quarters.
Silverarc Capital Management's Pliant Therapeutics position peaked at $17.3M in Q4 2024.
140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on Silverarc Capital Management's 13F filing for Q1 2025, filed 14 May 2025.